HC Wainwright reaffirmed their purchase score on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a report printed on Monday morning, Benzinga experiences. They presently have a $80.00 goal value on the biopharmaceutical firm’s inventory.
Different analysts additionally lately issued analysis experiences in regards to the inventory. Citigroup started protection on shares of Celldex Therapeutics in a report on Monday, October seventh. They set a “purchase” score and a $70.00 value goal for the corporate. Cantor Fitzgerald reissued an “chubby” score and set a $67.00 goal value on shares of Celldex Therapeutics in a analysis be aware on Monday, September sixteenth. The Goldman Sachs Group began protection on Celldex Therapeutics in a analysis be aware on Monday, September thirtieth. They issued a “impartial” score and a $45.00 value goal on the inventory. Wolfe Analysis downgraded Celldex Therapeutics from an “outperform” score to a “peer carry out” score in a analysis report on Friday, September twenty seventh. Lastly, Wells Fargo & Firm raised shares of Celldex Therapeutics from a “maintain” score to a “strong-buy” score in a analysis report on Thursday, September twenty sixth. Two equities analysis analysts have rated the inventory with a maintain score, six have given a purchase score and one has issued a powerful purchase score to the corporate. In response to information from MarketBeat.com, Celldex Therapeutics presently has a consensus score of “Reasonable Purchase” and a median goal value of $62.25.
Learn Our Newest Inventory Evaluation on CLDX
Celldex Therapeutics Buying and selling Down 1.0 %
NASDAQ:CLDX opened at $26.06 on Monday. The corporate has a market cap of $1.73 billion, a P/E ratio of -9.51 and a beta of 1.55. Celldex Therapeutics has a twelve month low of $22.26 and a twelve month excessive of $53.18. The corporate’s 50-day transferring common value is $35.12 and its 200-day transferring common value is $36.34.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) final launched its earnings outcomes on Thursday, August eighth. The biopharmaceutical firm reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a damaging internet margin of 1,809.18% and a damaging return on fairness of 23.66%. The enterprise had income of $2.50 million for the quarter, in comparison with analyst estimates of $1.13 million. On common, analysts count on that Celldex Therapeutics will publish -2.5 earnings per share for the present 12 months.
Institutional Inflows and Outflows
Institutional traders have lately made modifications to their positions within the enterprise. Vanguard Group Inc. boosted its place in Celldex Therapeutics by 16.3% within the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical firm’s inventory valued at $120,817,000 after shopping for an extra 427,827 shares in the course of the interval. Novo Holdings A S boosted its holdings in Celldex Therapeutics by 13.4% within the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical firm’s inventory valued at $32,755,000 after buying an extra 113,663 shares in the course of the interval. Value T Rowe Associates Inc. MD grew its stake in Celldex Therapeutics by 631.1% in the course of the 1st quarter. Value T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical firm’s inventory price $129,571,000 after buying an extra 2,664,915 shares within the final quarter. Swiss Nationwide Financial institution grew its stake in Celldex Therapeutics by 17.8% in the course of the 1st quarter. Swiss Nationwide Financial institution now owns 114,300 shares of the biopharmaceutical firm’s inventory price $4,797,000 after buying an extra 17,300 shares within the final quarter. Lastly, Jennison Associates LLC elevated its holdings in Celldex Therapeutics by 3,327.0% in the course of the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical firm’s inventory price $28,879,000 after buying an extra 668,002 shares in the course of the interval.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical firm, engages in creating therapeutic monoclonal and bispecific antibodies for the remedy of varied illnesses. Its drug candidates embrace antibody-based therapeutics to deal with sufferers with inflammatory, allergic, autoimmune, and different devastating illnesses.
Featured Articles
Obtain Information & Rankings for Celldex Therapeutics Each day – Enter your electronic mail handle beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for Celldex Therapeutics and associated corporations with MarketBeat.com’s FREE day by day electronic mail e-newsletter.
